Matinas BioPharma Holdings Inc (MTNB)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $881,570
Last updated: Nov 17, 2026 at 11:05 AM ET
Matinas BioPharma Holdings Inc (MTNB) Earnings: Report Dates and Results
Matinas BioPharma Holdings (MTNB) is expected to report earnings on Mar 29, 2027. In the quarter ended Sep 30, 2026, Matinas BioPharma Holdings reported EPS of $6.00. It beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Next Report
MTNB has an expected report date of Mar 29, 2027.
MTNB Earnings Call
The latest MTNB earnings call transcript on file is labeled 2024Q2.
Read the 2024Q2 transcriptEarnings History
Of the 34 quarters below that had an estimate, MTNB beat 12, missed 5 and matched 17. The widest gap in the table came in the quarter ended Mar 31, 2017, when EPS landed 614.29% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $6.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 16, 2026 | N/A |
| Jun 30, 2026 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 13, 2026 | N/A |
| Mar 31, 2026 | -$0.30 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 8, 2026 | N/A |
| Dec 31, 2025 | -$4.48 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2026 | N/A |
| Sep 30, 2025 | -$0.40 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Nov 10, 2025 | N/A |
| Jun 30, 2025 | -$1.03 | N/A | N/A | N/A | N/A | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.33 | -$0.78 | N/A | +57.69% | Beat | N/A | N/A | 0 up, 0 down | Apr 15, 2025 | N/A |
| Dec 31, 2024 | -$0.81 | -$0.78 | -$0.78 - -$0.78 | -3.28% | Miss | N/A | 1 | 1 up, 0 down | Mar 26, 2025 | N/A |
| Sep 30, 2024 | -$0.85 | -$1.05 | -$1.11 - -$1.00 | +19.05% | Beat | N/A | 2 | 0 up, 1 down | Nov 13, 2024 | N/A |
| Jun 30, 2024 | -$0.02 | -$0.02 | -$0.03 - -$0.02 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 1 | 0 up, 0 down | May 9, 2024 | N/A |
| Dec 31, 2023 | -$0.02 | -$0.03 | N/A | +33.33% | Beat | N/A | N/A | 0 up, 0 down | Mar 27, 2024 | N/A |
| Sep 30, 2023 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 8, 2023 | N/A |
| Jun 30, 2023 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 2 | 0 up, 0 down | Aug 9, 2023 | N/A |
| Mar 31, 2023 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 1 | 0 up, 0 down | May 10, 2023 | $1.10M |
| Dec 31, 2022 | -$0.02 | -$0.03 | -$0.03 - -$0.02 | +33.33% | Beat | N/A | 3 | 0 up, 0 down | Mar 15, 2023 | $1.06M |
| Sep 30, 2022 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 4 | 0 up, 0 down | Nov 2, 2022 | $1.06M |
| Jun 30, 2022 | -$1.50 | -$1.50 | -$1.50 - -$1.50 | 0.00% | In line | N/A | 3 | 0 up, 0 down | Aug 11, 2022 | $1.06M |
| Mar 31, 2022 | -$1.50 | -$1.25 | -$1.50 - -$1.00 | -20.00% | Miss | N/A | 2 | 1 up, 0 down | May 12, 2022 | N/A |
| Dec 31, 2021 | -$0.03 | -$0.03 | -$0.04 - -$0.03 | 0.00% | In line | N/A | 3 | N/A | Mar 8, 2022 | N/A |
| Sep 30, 2021 | -$1.50 | -$1.50 | -$2.00 - $0.50 | 0.00% | In line | N/A | 4 | N/A | Nov 8, 2021 | N/A |
| Jun 30, 2021 | -$1.00 | -$1.75 | -$2.00 - -$0.50 | +42.86% | Beat | N/A | 4 | N/A | Aug 10, 2021 | N/A |
| Mar 31, 2021 | -$1.50 | -$1.50 | -$1.50 - -$1.00 | 0.00% | In line | N/A | 4 | N/A | May 10, 2021 | $33333 |
| Dec 31, 2020 | -$0.03 | -$0.03 | -$0.04 - -$0.01 | 0.00% | In line | N/A | 5 | N/A | Mar 29, 2021 | $62500 |
| Sep 30, 2020 | -$1.50 | -$1.67 | -$2.00 - -$1.50 | +10.18% | Beat | N/A | 6 | N/A | Nov 6, 2020 | $95833 |
| Jun 30, 2020 | -$1.50 | -$1.50 | -$2.00 - -$1.50 | 0.00% | In line | N/A | 6 | N/A | Aug 10, 2020 | N/A |
| Mar 31, 2020 | -$0.03 | -$0.03 | -$0.04 - -$0.02 | 0.00% | In line | N/A | 5 | N/A | May 11, 2020 | N/A |
| Dec 31, 2019 | -$1.83 | -$1.83 | -$2.00 - -$1.50 | 0.00% | In line | N/A | 6 | N/A | Mar 9, 2020 | N/A |
| Sep 30, 2019 | -$1.50 | -$2.00 | -$2.00 - -$1.50 | +25.00% | Beat | N/A | 4 | N/A | Nov 13, 2019 | N/A |
| Jun 30, 2019 | -$1.60 | -$2.00 | -$2.00 - -$1.50 | +20.00% | Beat | N/A | 4 | N/A | Aug 13, 2019 | $89812 |
| Mar 31, 2019 | -$2.00 | -$1.50 | -$1.50 - -$1.50 | -33.33% | Miss | N/A | 1 | N/A | Apr 2, 2019 | N/A |
| Dec 31, 2018 | -$0.03 | -$0.03 | -$0.04 - -$0.02 | 0.00% | In line | N/A | 2 | N/A | Dec 31, 2018 | $119750 |
| Sep 30, 2018 | -$1.50 | -$2.00 | N/A | +25.00% | Beat | N/A | N/A | N/A | Nov 12, 2018 | N/A |
| Jun 30, 2018 | -$2.00 | -$2.00 | -$2.00 - -$2.00 | 0.00% | In line | N/A | 1 | N/A | Aug 10, 2018 | $89813 |
| Mar 31, 2018 | -$2.50 | -$2.00 | -$2.00 - -$2.00 | -25.00% | Miss | N/A | 1 | N/A | May 10, 2018 | $29937 |
| Dec 31, 2017 | -$0.04 | -$0.04 | -$0.04 - -$0.04 | 0.00% | In line | N/A | 1 | N/A | Mar 26, 2018 | $44906 |
| Sep 30, 2017 | -$2.00 | -$2.33 | -$2.50 - -$2.00 | +14.16% | Beat | N/A | 2 | N/A | Nov 15, 2017 | $44906 |
| Jun 30, 2017 | -$2.00 | -$2.33 | -$2.50 - -$2.00 | +14.16% | Beat | N/A | 3 | N/A | Aug 8, 2017 | $44906 |
| Mar 31, 2017 | -$12.50 | -$1.75 | -$2.00 - -$1.50 | -614.29% | Miss | N/A | 2 | N/A | Apr 3, 2017 | $14969 |
| Dec 31, 2016 | -$0.03 | -$0.08 | N/A | +62.50% | Beat | N/A | N/A | N/A | Mar 31, 2017 | $2.27M |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$6.24, after -$3.18 the year before. It was -$5.60 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$6.24 | N/A |
| Dec 31, 2024 | -$3.18 | N/A |
| Dec 31, 2023 | -$4.52 | N/A |
| Dec 31, 2022 | -$4.52 | N/A |
| Dec 31, 2021 | -$4.03 | N/A |
| Dec 31, 2020 | -$3.06 | N/A |
| Dec 31, 2019 | -$6.93 | N/A |
| Dec 31, 2018 | -$6.03 | N/A |
| Dec 31, 2017 | -$16.54 | N/A |
| Dec 31, 2016 | -$5.60 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 3,300 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q2 | Jun 30, 2024 | 3,269 | 7 |
2024Q2 Earnings Call
Opening remarks
Jody Cain Investor Relations This is Jody Cain with LHA. Thank you for participating in today's call. Joining me from Matinas BioPharma are Jerry Jabbour, Chief Executive Officer; and Keith Kucinski, Chief Financial Officer. Dr. Terri Matkovits, Chief Development Officer; and Dr. Terry Ferguson, Chief Medical Officer, will be available during the question-and-answer session. I'd like to remind listeners that remarks made during this call may state management's future intentions, hopes, beliefs, expectations or projections. These are forward-looking statements that involve risks and uncertainties, forward-looking statements made pursuant to the safe harbor provisions of federal securities laws. These forward-looking statements are based on current expectations, and actual results could differ materially. As a result, you should not place undue reliance on forward-looking statements. Some of the factors that could cause actual results to differ materially from those contemplated by such forward-looking statements are discussed in the periodic reports Matinas BioPharma files with the Securities and Exchange Commission. These documents are available in the Investors section of the company's website and on sec.gov. Furthermore, the content of this conference call contains information that is accurate only as of the date of the live broadcast, August 14, 2024. Matinas BioPharma undertakes no obligation to revise or update any statements to reflect events or circumstances, except as required by law. And now I'd like to turn the call over to Jerry Jabbour. Jerry?
Jerry Jabbour CEO Thank you, Jody. Good afternoon, everyone, and thank you for joining us. We're pleased to begin today's call by reporting that we have signed a non-binding term sheet for the licensing of global rights to develop, manufacture and commercialize MAT2203. Our ongoing constructive dialogues to partner this oral formulation of the potent yet toxic antifungal amphotericin B cover not only the initial indication of patients with invasive aspergillosis with limited or no treatment options, but potentially all future treatment indications. We believe we have identified the right partner to maximize MAT2203's value in multiple territories. Our discussions have been quite productive and have covered a wide range of topics from development strategy and commercial manufacturing to regulatory and commercial positioning. We must state that this is a non-binding term sheet, and there is no guarantee that it will result in a definitive agreement, but we are very encouraged by this progress. Partnering this life-changing asset has been our top priority, and we've now taken a significant step forward in that process. We are confident that we are on a path to placing this asset in highly capable hands, which is in the best interest of our company and our shareholders.
Frequently Asked Questions About MTNB
When is Matinas BioPharma Holdings's next earnings date?
Matinas BioPharma Holdings's next earnings report is expected for Mar 29, 2027.
How often does MTNB beat earnings estimates?
Matinas BioPharma Holdings beat the EPS estimate in 3 of the 8 most recent quarters that had an estimate, with an average surprise of +13.35%.
MTNB pages: Overview, Earnings, Financials, Competitors